Use of recombinant tissue plasminogen activator in cancer patients with acute stroke

Jerome J. Graber, Lakshmi Nayak, Lisa M. DeAngelis

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

People with cancer may be at increased risk for stroke, especially of cardioembolic and large vessel origin. Some clinicians are reluctant to use recombinant tissue plasminogen activator (rTPA) in the cancer population due to safety concerns. We conducted a retrospective review of patients who received rTPA for acute stroke at an academic cancer center. We report six patients with cancer treated with rTPA at our institution, four of whom had early neurologic recovery. Only one of our six patients suffered minor bleeding as a complication of rTPA. Acute stroke in patients with cancer may be treated with rTPA, and active cancer should not be considered an absolute contraindication to rTPA use.

Original languageEnglish (US)
Pages (from-to)571-573
Number of pages3
JournalJournal of Neuro-Oncology
Volume107
Issue number3
DOIs
StatePublished - May 2012
Externally publishedYes

Fingerprint

Tissue Plasminogen Activator
Stroke
Neoplasms
Nervous System
Hemorrhage
Safety
Population

Keywords

  • Cancer
  • Malignancy
  • Neoplasm
  • Recombinant tissue plasminogen activator
  • Stroke
  • TPA

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Use of recombinant tissue plasminogen activator in cancer patients with acute stroke. / Graber, Jerome J.; Nayak, Lakshmi; DeAngelis, Lisa M.

In: Journal of Neuro-Oncology, Vol. 107, No. 3, 05.2012, p. 571-573.

Research output: Contribution to journalArticle

Graber, Jerome J. ; Nayak, Lakshmi ; DeAngelis, Lisa M. / Use of recombinant tissue plasminogen activator in cancer patients with acute stroke. In: Journal of Neuro-Oncology. 2012 ; Vol. 107, No. 3. pp. 571-573.
@article{a2b7596ac0d041a4aab27e32d0fb94f3,
title = "Use of recombinant tissue plasminogen activator in cancer patients with acute stroke",
abstract = "People with cancer may be at increased risk for stroke, especially of cardioembolic and large vessel origin. Some clinicians are reluctant to use recombinant tissue plasminogen activator (rTPA) in the cancer population due to safety concerns. We conducted a retrospective review of patients who received rTPA for acute stroke at an academic cancer center. We report six patients with cancer treated with rTPA at our institution, four of whom had early neurologic recovery. Only one of our six patients suffered minor bleeding as a complication of rTPA. Acute stroke in patients with cancer may be treated with rTPA, and active cancer should not be considered an absolute contraindication to rTPA use.",
keywords = "Cancer, Malignancy, Neoplasm, Recombinant tissue plasminogen activator, Stroke, TPA",
author = "Graber, {Jerome J.} and Lakshmi Nayak and DeAngelis, {Lisa M.}",
year = "2012",
month = "5",
doi = "10.1007/s11060-011-0780-5",
language = "English (US)",
volume = "107",
pages = "571--573",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Use of recombinant tissue plasminogen activator in cancer patients with acute stroke

AU - Graber, Jerome J.

AU - Nayak, Lakshmi

AU - DeAngelis, Lisa M.

PY - 2012/5

Y1 - 2012/5

N2 - People with cancer may be at increased risk for stroke, especially of cardioembolic and large vessel origin. Some clinicians are reluctant to use recombinant tissue plasminogen activator (rTPA) in the cancer population due to safety concerns. We conducted a retrospective review of patients who received rTPA for acute stroke at an academic cancer center. We report six patients with cancer treated with rTPA at our institution, four of whom had early neurologic recovery. Only one of our six patients suffered minor bleeding as a complication of rTPA. Acute stroke in patients with cancer may be treated with rTPA, and active cancer should not be considered an absolute contraindication to rTPA use.

AB - People with cancer may be at increased risk for stroke, especially of cardioembolic and large vessel origin. Some clinicians are reluctant to use recombinant tissue plasminogen activator (rTPA) in the cancer population due to safety concerns. We conducted a retrospective review of patients who received rTPA for acute stroke at an academic cancer center. We report six patients with cancer treated with rTPA at our institution, four of whom had early neurologic recovery. Only one of our six patients suffered minor bleeding as a complication of rTPA. Acute stroke in patients with cancer may be treated with rTPA, and active cancer should not be considered an absolute contraindication to rTPA use.

KW - Cancer

KW - Malignancy

KW - Neoplasm

KW - Recombinant tissue plasminogen activator

KW - Stroke

KW - TPA

UR - http://www.scopus.com/inward/record.url?scp=84864328560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864328560&partnerID=8YFLogxK

U2 - 10.1007/s11060-011-0780-5

DO - 10.1007/s11060-011-0780-5

M3 - Article

C2 - 22179814

AN - SCOPUS:84864328560

VL - 107

SP - 571

EP - 573

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -